RU2017113775A - Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция - Google Patents

Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция Download PDF

Info

Publication number
RU2017113775A
RU2017113775A RU2017113775A RU2017113775A RU2017113775A RU 2017113775 A RU2017113775 A RU 2017113775A RU 2017113775 A RU2017113775 A RU 2017113775A RU 2017113775 A RU2017113775 A RU 2017113775A RU 2017113775 A RU2017113775 A RU 2017113775A
Authority
RU
Russia
Prior art keywords
nrg
ventricular
pharmaceutical preparation
composition
mammal
Prior art date
Application number
RU2017113775A
Other languages
English (en)
Russian (ru)
Other versions
RU2017113775A3 (cg-RX-API-DMAC7.html
Inventor
Миндун ЧЖОУ
Original Assignee
Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55580273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017113775(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед filed Critical Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед
Publication of RU2017113775A publication Critical patent/RU2017113775A/ru
Publication of RU2017113775A3 publication Critical patent/RU2017113775A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017113775A 2014-09-24 2015-09-06 Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция RU2017113775A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410529437.4A CN105497876B (zh) 2014-09-24 2014-09-24 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN201410529437.4 2014-09-24
PCT/CN2015/088972 WO2016045493A1 (zh) 2014-09-24 2015-09-06 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物

Publications (2)

Publication Number Publication Date
RU2017113775A true RU2017113775A (ru) 2018-10-26
RU2017113775A3 RU2017113775A3 (cg-RX-API-DMAC7.html) 2019-04-04

Family

ID=55580273

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017113775A RU2017113775A (ru) 2014-09-24 2015-09-06 Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция

Country Status (9)

Country Link
US (1) US10441633B2 (cg-RX-API-DMAC7.html)
EP (1) EP3199174B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017530127A (cg-RX-API-DMAC7.html)
KR (1) KR20170055492A (cg-RX-API-DMAC7.html)
CN (2) CN105497876B (cg-RX-API-DMAC7.html)
AU (1) AU2015320230B2 (cg-RX-API-DMAC7.html)
CA (1) CA2961813A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017113775A (cg-RX-API-DMAC7.html)
WO (1) WO2016045493A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. ニューレグリンに基づく心不全の治療方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
US12295930B2 (en) * 2018-08-14 2025-05-13 Emory University Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US12649769B2 (en) 2019-09-16 2026-06-09 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
EP1028735A4 (en) 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN101146527A (zh) 2005-01-20 2008-03-19 詹森药业有限公司 Qt间期控制的方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CN101310766B (zh) * 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US8603817B2 (en) * 2008-11-03 2013-12-10 University Of Washington Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
WO2010142141A1 (en) 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
US20120028992A1 (en) * 2010-08-02 2012-02-02 Brown Arthur M Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
US9447027B2 (en) 2010-10-22 2016-09-20 The General Hospital Corporation Treating long QT syndrome
CN102302552A (zh) * 2011-08-31 2012-01-04 朱明军 一种治疗心律失常的胶囊及其制备方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
EP3027190A1 (en) 2013-08-01 2016-06-08 Gilead Sciences, Inc. Compound and methods for treating long qt syndrome
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Also Published As

Publication number Publication date
CN105497876B (zh) 2021-01-15
KR20170055492A (ko) 2017-05-19
US20170368140A1 (en) 2017-12-28
EP3199174B1 (en) 2022-04-13
RU2017113775A3 (cg-RX-API-DMAC7.html) 2019-04-04
CN105497876A (zh) 2016-04-20
CN110337304A (zh) 2019-10-15
JP2017530127A (ja) 2017-10-12
US10441633B2 (en) 2019-10-15
AU2015320230A1 (en) 2017-03-30
EP3199174A4 (en) 2018-06-06
CA2961813A1 (en) 2016-03-31
EP3199174A1 (en) 2017-08-02
WO2016045493A1 (zh) 2016-03-31
AU2015320230B2 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
CN110337304A (zh) 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
JP2017532343A5 (cg-RX-API-DMAC7.html)
PH12020551205A1 (en) Fap inhibitors
EA201800367A1 (ru) Способы лечения болезни хантингтона
EP4559481A3 (en) Methods of treatment of cholestatic diseases
EP4616914A3 (en) Polypeptides binding to human complement c5
EA201990071A1 (ru) Композиция пептидной вакцины
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
RU2018117862A (ru) Новый полипептид с аффинностью к PD-L1
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
WO2016014533A3 (en) Devices and methods for fixation of animal tissue
TN2020000069A1 (en) Anti-alpha-synuclein antibodies
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
WO2017103094A3 (en) Means and methods for treating copper-related diseases
WO2016133152A3 (ja) 蛋白質吸着抑制方法
JP2017530127A5 (cg-RX-API-DMAC7.html)
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
EP3851099C0 (en) COMPOSITION INTENDED FOR THE TREATMENT OF FIBROTIC DISEASES, COMPRISING BENZHYDRYL THIOACETAMIDE AS THE ACTIVE INGREDIENT
WO2017029558A3 (en) Methods for improving health of farmed fish
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200730